Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 14, 2019 - Issue
Submit an article Journal homepage
111
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study

Alan Kaplan1 Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada, [email protected]Correspondence[email protected]
,
Kenneth R Chapman2 Division of Respiratory Medicine, Department of Medicine, University of Toronto, Toronto, ON, Canada
,
Syed M Anees3 Schulich School of Medicine & Dentistry – Western University, University of Windsor, ON, Canada
,
Irvin Mayers4 Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada
,
Driss Rochdi5 Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada
,
Michel Djandji5 Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada
,
David Préfontaine5 Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada
&
Andrew McIvor6 Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, ON, Canada
 show all
Pages 249-260 | Published online: 18 Jan 2019

Figures & data

Figure 1 Study design.

Note: POWER study design (groups switched to IND/GLY).
Abbreviations: bid, twice daily; h, hours; IND/GLY, indacaterol/glycopyrronium; od, once daily; SFC, salmeterol/fluticasone.
Figure 1 Study design.

Figure 2 Patient disposition.

Note: Data are presented as n (%).
Figure 2 Patient disposition.

Table 1 Baseline demographics and clinical characteristics

Figure 3 Change from baseline in trough FEV1 at Week 16 (ITT population).

Notes: Data are presented as mean ± 95% CI. Δ, change from baseline.
Abbreviations: IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; SFC, salmeterol/fluticasone; Tio, tiotropium.
Figure 3 Change from baseline in trough FEV1 at Week 16 (ITT population).

Figure 4 Change from baseline in trough FEV1 at Week 4 (ITT population).

Notes: Data are presented as mean ± 95% CI. Δ, change from baseline.
Abbreviations: IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; SFC, salmeterol/fluticasone; Tio, tiotropium.
Figure 4 Change from baseline in trough FEV1 at Week 4 (ITT population).

Figure 5 Change from baseline in TDI score at Week 16 (ITT population).

Notes: Data are presented as mean ± 95% CI. The dotted line represents MCID.
Abbreviations: IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; MCID, minimal clinically important difference; SFC, salmeterol/fluticasone; TDI, transition dyspnea index; Tio, tiotropium.
Figure 5 Change from baseline in TDI score at Week 16 (ITT population).

Figure 6 Change from baseline in CAT score at Week 16 (ITT population).

Note: Data are presented as mean ± 95% CI.
Abbreviations: CAT, COPD assessment test; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; SFC, salmeterol/fluticasone; Tio, tiotropium.
Figure 6 Change from baseline in CAT score at Week 16 (ITT population).

Figure 7 Change from baseline in trough FEV1 at Week 16 by subgroups.

Note: Data are presented as mean (95% CI).
Figure 7 Change from baseline in trough FEV1 at Week 16 by subgroups.

Table 2 Treatment-emergent AEs and SAEs during the study period (safety set)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.